Korean Biotechs Battle For Funding and Attention Underneath Chinese Shadow
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korean biotechs are producing siginificant R&D output, but there is a disconnect between local companies' scientific and financial success, and the country needs to utilize new models to build a viable biotech industry, according to panelists at Bio Korea 2010
You may also be interested in...
Korea Trying To Carve Out Large Share of Early-stage Clinical Trial Work In Asia - Bio Korea 2010
SEOUL - The Korean clinical trial industry is hoping to distinguish itself as a draw for early-stage clinical trials, trying to find ground in a clinical trial environment that puts the focus on trial work in emerging markets in countries like China and India
Korea Trying To Carve Out Large Share of Early-stage Clinical Trial Work In Asia - Bio Korea 2010
SEOUL - The Korean clinical trial industry is hoping to distinguish itself as a draw for early-stage clinical trials, trying to find ground in a clinical trial environment that puts the focus on trial work in emerging markets in countries like China and India
Korea Trying To Carve Out Large Share of Early-Stage Clinical Trial Work In Asia - Bio Korea 2010
The reasons to come to Asia are high disease prevalence, clinical expertise and a vibrant R&D environment, but capitalizing on each country's strengths is the key to success, according to J&J Senior Director, Asia Pacific Global Clinical Operations, Aakash Ganju,.